vTv Therapeutics (STU:5VT0) FCF Margin %: 24.85% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5VT0 vTv Therapeutics Inc STU:5VT0
33 GF Score
Price €27.20
View Full Analysis

What is vTv Therapeutics FCF Margin %?

vTv Therapeutics STU:5VT0 33 FCF Margin % is 24.85% as of Mar. 2026. GuruFocus rates STU:5VT0 with a GF Score™ of 33/100. Among 950 Biotechnology companies, vTv Therapeutics ranks better than 60.42% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. vTv Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €7.92 Mil. vTv Therapeutics's Revenue for the three months ended in Mar. 2026 was €31.87 Mil. Therefore, vTv Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 24.85%.

As of today, vTv Therapeutics's current FCF Yield % is -8.35%.

The historical rank and industry rank for vTv Therapeutics's FCF Margin % or its related term are showing as below:

STU:5VT0' s FCF Margin % Range Over the Past 10 Years
Min: -15332.3   Med: -815.16   Max: -27.77
Current: -27.77


During the past 13 years, the highest FCF Margin % of vTv Therapeutics was -27.77%. The lowest was -15332.30%. And the median was -815.16%.

STU:5VT0's FCF Margin % is ranked better than
60.42% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs STU:5VT0: -27.77


vTv Therapeutics FCF Margin % Related Terms


vTv Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics FCF Margin % Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -482.17 -795.01 0.00 -2,488.98 0.00

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 24.85

STU:5VT0 vs SMNR, CNTB, ENLV: FCF Margin % Comparison

For the Biotechnology subindustry, vTv Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's FCF Margin % falls into.


STU:5VT0
33GF Score
vTv Therapeutics Inc STU:5VT0
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

vTv Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-21.568/0
= %

vTv Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=7.918/31.866
=24.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 24.85% mean?
vTv Therapeutics (STU:5VT0) has a FCF Margin % of 24.85% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #376 out of 950 companies in the Biotechnology industry, placing it in the top 39.6%.
Is vTv Therapeutics' FCF Margin % too high?
vTv Therapeutics' current FCF Margin % is 24.85%. Based on the distribution chart, vTv Therapeutics ranks #376 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' FCF Margin % compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #376 out of 950 companies for FCF Margin %. This puts vTv Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current FCF Margin % is 24.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (STU:5VT0) has a current FCF Margin % of 24.85%. The current FCF Margin % is 24.85%. vTv Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For vTv Therapeutics (STU:5VT0), the current FCF Margin % is 24.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
33GF Score

Get the complete analysis for STU:5VT0

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.20
Price